{"id":"de-prescribe-beta-blocker-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Rebound hypertension"},{"rate":null,"effect":"Rebound tachycardia"},{"rate":null,"effect":"Angina pectoris exacerbation"}]},"_chembl":{"chemblId":"CHEMBL1402326","moleculeType":"Small molecule","molecularWeight":"540.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"De-prescribing beta blockers involves a structured, evidence-based approach to safely withdraw these medications in patients who may no longer benefit from them or who are at risk of harm from continued use. The protocol typically includes patient assessment, gradual dose reduction to avoid rebound hypertension or tachycardia, and monitoring for adverse effects during the withdrawal process. This is a clinical practice guideline rather than a pharmacological agent.","oneSentence":"This is a clinical deprescribing protocol that guides the gradual discontinuation of beta-blocker medications in patients for whom continued therapy is no longer indicated.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:10.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Safe discontinuation of beta-blocker therapy in patients with resolved or changed clinical indications"},{"name":"Reduction of polypharmacy and adverse effects in elderly patients or those with contraindications to beta-blockers"}]},"trialDetails":[{"nctId":"NCT04788186","phase":"PHASE4","title":"Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).","status":"UNKNOWN","sponsor":"University of Saskatchewan","startDate":"2021-08-23","conditions":"Coronary Artery Disease, Acute Myocardial Infarction, Coronary Artery Stenosis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["De-prescription"],"phase":"marketed","status":"active","brandName":"De-prescribe beta blocker therapy","genericName":"De-prescribe beta blocker therapy","companyName":"University of Saskatchewan","companyId":"university-of-saskatchewan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a clinical deprescribing protocol that guides the gradual discontinuation of beta-blocker medications in patients for whom continued therapy is no longer indicated. Used for Safe discontinuation of beta-blocker therapy in patients with resolved or changed clinical indications, Reduction of polypharmacy and adverse effects in elderly patients or those with contraindications to beta-blockers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}